Zelba et al. indicated that PD-1 and LAG-3 co-blockade might be a potential treatment option for advanced ccRCC since these inhibitor receptors (IRs) were found to be similarly expressed. This evidence concerns the gene LAG3 and nonpapillary renal cell carcinoma.